FR11C0035I2 - Suspensions aqueuses d'esters d'acides gras de 9-hydroxyrisperidone - Google Patents

Suspensions aqueuses d'esters d'acides gras de 9-hydroxyrisperidone

Info

Publication number
FR11C0035I2
FR11C0035I2 FR11C0035C FR11C0035C FR11C0035I2 FR 11C0035 I2 FR11C0035 I2 FR 11C0035I2 FR 11C0035 C FR11C0035 C FR 11C0035C FR 11C0035 C FR11C0035 C FR 11C0035C FR 11C0035 I2 FR11C0035 I2 FR 11C0035I2
Authority
FR
France
Prior art keywords
fatty acid
acid esters
aqueous suspensions
hydroxyrisperidone fatty
hydroxyrisperidone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR11C0035C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0035(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of FR11C0035I1 publication Critical patent/FR11C0035I1/fr
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of FR11C0035I2 publication Critical patent/FR11C0035I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
FR11C0035C 1996-05-20 2011-09-02 Suspensions aqueuses d'esters d'acides gras de 9-hydroxyrisperidone Active FR11C0035I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20
PCT/EP1997/002504 WO1997044039A1 (en) 1996-05-20 1997-05-12 Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
EP97923912A EP0904081B1 (de) 1996-05-20 1997-05-12 Wässrige suspension von 9-hydroxyrisperidon-fettsäureester

Publications (2)

Publication Number Publication Date
FR11C0035I1 FR11C0035I1 (de) 2011-07-10
FR11C0035I2 true FR11C0035I2 (fr) 2013-08-16

Family

ID=8224016

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0035C Active FR11C0035I2 (fr) 1996-05-20 2011-09-02 Suspensions aqueuses d'esters d'acides gras de 9-hydroxyrisperidone

Country Status (37)

Country Link
US (1) US6077843A (de)
EP (1) EP0904081B1 (de)
JP (1) JP3274687B2 (de)
KR (1) KR100358373B1 (de)
CN (1) CN1093762C (de)
AR (1) AR007194A1 (de)
AT (1) ATE208619T1 (de)
AU (1) AU715572B2 (de)
BG (1) BG62684B1 (de)
BR (1) BR9706824B8 (de)
CA (1) CA2236691C (de)
CY (2) CY2270B1 (de)
CZ (1) CZ291284B6 (de)
DE (2) DE122011100027I1 (de)
DK (1) DK0904081T3 (de)
EA (1) EA000536B1 (de)
EE (1) EE03594B1 (de)
ES (1) ES2167745T3 (de)
FR (1) FR11C0035I2 (de)
HR (1) HRP970276B1 (de)
HU (2) HU224025B1 (de)
ID (1) ID16927A (de)
IL (1) IL124551A (de)
LU (1) LU91842I2 (de)
MX (1) MX9804816A (de)
MY (1) MY126302A (de)
NO (2) NO315931B1 (de)
NZ (1) NZ330369A (de)
PL (1) PL188309B1 (de)
PT (1) PT904081E (de)
SI (1) SI0904081T1 (de)
SK (1) SK284013B6 (de)
TR (1) TR199800923T2 (de)
TW (1) TW487572B (de)
UA (1) UA61898C2 (de)
WO (1) WO1997044039A1 (de)
ZA (1) ZA974331B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
AU753278B2 (en) * 1998-02-25 2002-10-10 Abbott Laboratories Butorphanol sustained release formulations
US6342488B1 (en) * 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
PL198797B1 (pl) 1999-03-31 2008-07-31 Janssen Pharmaceutica Nv Zastosowanie wstępnie żelowanej skrobi
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
MXPA03001337A (es) * 2000-08-14 2005-06-30 Teva Pharma Preparacion de risperidona.
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
RU2321391C2 (ru) * 2002-07-29 2008-04-10 Алза Корпорейшн Способы и лекарственные формы для контролируемой доставки палиперидона
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
BRPI0415531B8 (pt) 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
CA2553254C (en) * 2004-01-12 2013-12-17 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP5249748B2 (ja) 2005-04-25 2013-07-31 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 無菌３−［２−［４−（６−フルオロ−１，２−ベンズイソオキサゾール−３−イル）−１−ピペリジニル］エチル］−６，７，８，９−テトラヒドロ−９−ヒドロキシ−２−メチル−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンパルミチン酸エステルの製造
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US8314110B2 (en) * 2007-04-19 2012-11-20 Youxin Li Compounds for treating mental disorders, and preparation and uses thereof
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
CN101932327A (zh) * 2007-12-19 2010-12-29 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案
WO2009089076A2 (en) * 2008-01-10 2009-07-16 Teva Pharmaceutical Industries Ltd. Processes for the preparation and purification of paliperidone palmitate
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
SMT202000405T1 (it) 2008-09-04 2020-09-10 Amylin Pharmaceuticals Llc Formulazioni a rilascio prolungato usando veicolanti non acquosi
MX378797B (es) 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
KR20120116401A (ko) 2009-10-30 2012-10-22 얀센 파마슈티카 엔.브이. 장기-작용성의 주사가능한 팔리페리돈 에스테르와 관련된 투약 요법
US20120259116A1 (en) * 2009-12-17 2012-10-11 Rajiv Kumar Novel Process for the Preparation of Paliperidone
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
CN107595771A (zh) 2010-10-18 2018-01-19 大日本住友制药株式会社 注射用缓释制剂
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012164582A1 (en) 2011-05-31 2012-12-06 Ramamohan Rao Davuluri Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydro-9-hydroxy-2-methyl-4h-pyrido[ 1, 2-a]-pyrimidin-4-one (paliperidone) and paliperidone palmitate.
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
FI3744326T3 (fi) 2015-04-07 2024-02-02 Janssen Pharmaceutica Nv Annosteluohjelma pitkävaikutteisten injektoitavien paliperidoniestereiden ottamatta jääneille annoksille
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
CA3203015A1 (en) 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
CN116528837B (zh) 2020-11-30 2025-03-14 詹森药业有限公司 用于确保棕榈酸帕潘立酮制剂再悬浮的方法
SMT202400077T1 (it) 2020-11-30 2024-03-13 Janssen Pharmaceutica Nv Regimi di dosaggio associati con formulazioni iniettabili di paliperidone a rilascio prolungato
MX2023006370A (es) 2020-11-30 2023-08-07 Janssen Pharmaceutica Nv Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
CA2000786C (en) * 1988-11-07 1999-01-26 Janssen Pharmaceutica, Naamloze Vennootschap 3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
ATE288270T1 (de) * 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
EP2283821A1 (de) * 1993-11-19 2011-02-16 Alkermes, Inc. Herstellung biodegradierbarer Mikroteilchen, die ein biologisch aktives Mittel enthalten
JP3057763B2 (ja) * 1995-06-06 2000-07-04 ヘキスト・マリオン・ルセル・インコーポレイテツド 抗精神病薬としてのベンゾイソオキサゾール及びインダゾール誘導体
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
TW487572B (en) 2002-05-21
CN1093762C (zh) 2002-11-06
NO981984L (no) 1998-11-19
SK62098A3 (en) 2000-04-10
NO2011015I2 (no) 2013-03-11
JP3274687B2 (ja) 2002-04-15
PL188309B1 (pl) 2005-01-31
PL327995A1 (en) 1999-01-04
HRP970276B1 (en) 2002-04-30
CY2011011I2 (el) 2016-12-14
IL124551A0 (en) 1998-12-06
SI0904081T1 (en) 2002-04-30
IL124551A (en) 2001-08-26
US6077843A (en) 2000-06-20
NO981984D0 (no) 1998-04-30
ZA974331B (en) 1998-11-19
BG102443A (en) 1999-06-30
HU224025B1 (hu) 2005-05-30
NO315931B1 (no) 2003-11-17
DK0904081T3 (da) 2002-02-25
HRP970276A2 (en) 1998-04-30
CN1206347A (zh) 1999-01-27
CA2236691C (en) 2007-01-02
JP2000513718A (ja) 2000-10-17
EP0904081A1 (de) 1999-03-31
DE69708284T2 (de) 2002-07-25
CZ140198A3 (cs) 1999-04-14
BG62684B1 (bg) 2000-05-31
AU2955997A (en) 1997-12-09
AR007194A1 (es) 1999-10-13
PT904081E (pt) 2002-04-29
AU715572B2 (en) 2000-02-03
MY126302A (en) 2006-09-29
EA000536B1 (ru) 1999-10-28
MX9804816A (es) 1998-10-31
SK284013B6 (sk) 2004-08-03
FR11C0035I1 (de) 2011-07-10
KR19990067603A (ko) 1999-08-25
DE69708284D1 (de) 2001-12-20
CY2270B1 (en) 2003-07-04
NZ330369A (en) 2000-04-28
EP0904081B1 (de) 2001-11-14
BR9706824A (pt) 1999-03-23
CY2011011I1 (el) 2016-12-14
KR100358373B1 (ko) 2003-02-11
ID16927A (id) 1997-11-20
CZ291284B6 (cs) 2003-01-15
HK1017852A1 (en) 1999-12-03
BR9706824B8 (pt) 2015-02-18
NO2011015I1 (no) 2011-09-19
UA61898C2 (en) 2003-12-15
EE03594B1 (et) 2002-02-15
DE122011100027I1 (de) 2011-11-17
HUP9901319A3 (en) 1999-11-29
WO1997044039A1 (en) 1997-11-27
HUS1100013I1 (hu) 2017-03-28
HUP9901319A2 (hu) 1999-08-30
TR199800923T2 (xx) 1999-09-21
ATE208619T1 (de) 2001-11-15
EE9800136A (et) 1998-10-15
EA199800531A1 (ru) 1998-12-24
ES2167745T3 (es) 2002-05-16
LU91842I2 (fr) 2011-09-20
CA2236691A1 (en) 1997-11-27

Similar Documents

Publication Publication Date Title
DE69708284D1 (de) Wässrige suspension von 9-hydroxyrisperidon-fettsäureester
DE69814451D1 (de) Wässrige suspensionen von submikron 9-hydroxyrisperidon fettsäureestern
FI963867A7 (fi) Rasvahappoestereiden käyttö bioadhesiivisina aineina
ITPD940043A0 (it) "esteri attivi di polisaccaridi carbossilici"
PT823895E (pt) Esteres de acidos gordos como composto bioactivos
PT0900782E (pt) Ester do acido 2-cianacrilico
DE69625843D1 (de) Ester aus Dextrin und Fettsäuren und dessen Verwendung
EP0986296A4 (de) Fettsäureelongase
DE59913680D1 (de) Fettsäurepartialester von Polyolen
IL115594A0 (en) Preparation of alpha-tertiary carboxylic acid esters
FR2722798B1 (fr) 1procede de production d'acides gras2plantes oleagineuses
FR2782638B1 (fr) Utilisation en cosmetique d'acides gras
FR2757165B1 (fr) Ester de l'acide maleimidobenzoique
DE59404990D1 (de) Fettsäureester von Methylglucosid-Derivaten
IL122919A0 (en) Preparation of 1-alkyl-pyrazole-5-carboxylic acid esters
DE69809692D1 (de) Herstellung von Carbonsäureestern